Knowledge Distillery

The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19.

CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years…

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India. It has since then become dominant in some indian regions and UK and further…

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for…

The objective of this prospective, multicentre, observational cohort study was to assess neurological manifestations and quality of life (QoL) three…

This review focuses on new evidence supporting the global immunization strategy for MS patients receiving disease-modifying drugs (DMDs), including…

Acute delirium and other neuropsychiatric symptoms have frequently been reported in COVID-19 patients and are variably referred to as acute…

Whilst respiratory failure in COVID-19 arises from severe interstitial lung involvement, SARS-CoV-2 likely spreads also through the nervous system.

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in…

The deployment of a vaccine that limits transmission and disease likely will be required to end the COVID-19 pandemic.

Continued uncontrolled transmission of the SARS-CoV-2 in many parts of the world is creating the conditions for significant virus evolution.

Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan, China, in December 2019, the novel coronavirus that causes…